Published in Semin Thromb Hemost on January 01, 2000
Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol (2007) 2.67
Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol (1985) (2009) 1.76
Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunction. Am J Physiol Cell Physiol (2008) 1.35
l-Citrulline and l-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits. Proc Natl Acad Sci U S A (2005) 1.19
Epidemiology of preeclampsia: impact of obesity. Nutr Rev (2013) 0.97
Mechanisms of nitric oxide synthase uncoupling in endotoxin-induced acute lung injury: role of asymmetric dimethylarginine. Vascul Pharmacol (2009) 0.90
Impact of ADMA, endothelial progenitor cells and traditional cardiovascular risk factors on pulse wave velocity among prediabetic individuals. Cardiovasc Diabetol (2012) 0.85
Intravenous and gastric cerium dioxide nanoparticle exposure disrupts microvascular smooth muscle signaling. Toxicol Sci (2014) 0.81
Homocysteine and asymmetric dimethylarginine in relation to B vitamins in elderly people. Wien Klin Wochenschr (2011) 0.80
Dimethylarginine dimethylaminohydrolase II overexpression attenuates LPS-mediated lung leak in acute lung injury. Am J Respir Cell Mol Biol (2014) 0.80
Antioxidants in Cardiovascular Therapy: Panacea or False Hope? Front Cardiovasc Med (2015) 0.78
Risk of cardiovascular diseases in diabetes mellitus and serum concentration of asymmetrical dimethylarginine. Biochem Res Int (2013) 0.76
Mechanistic studies of inactivation of inducible nitric oxide synthase by amidines. Biochemistry (2015) 0.75
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation (1998) 3.25
Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation (1997) 2.20
LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res (2000) 1.76
Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) (2001) 1.59
Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest (2003) 1.49
The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol (2001) 1.46
Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther (2000) 1.44
Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol (1999) 1.32
Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett (2000) 1.29
Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol (2000) 1.17
An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol (2000) 1.10
Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation (1997) 1.04
N(G)-nitro-L-arginine- and indomethacin-resistant endothelium-dependent relaxation in the rabbit renal artery: effect of hypercholesterolemia. Atherosclerosis (1997) 1.01
Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis (1995) 1.01
Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest (1996) 1.00
Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol (1998) 0.96
Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs. J Chromatogr B Biomed Appl (1994) 0.91
Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol (2001) 0.90
Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol (2000) 0.89
Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. Clin Nephrol (2004) 0.88
Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis (1998) 0.87
Dietary L-arginine and alpha-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Atherosclerosis (1998) 0.86
Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose aspirin. J Appl Physiol (1985) (1995) 0.85
Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res (2004) 0.85
Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol. Clin Pharmacol Ther (2010) 0.83
L-arginine supplementation in hypercholesterolemic rabbits normalizes leukocyte adhesion to non-endothelial matrix. Life Sci (2000) 0.83
Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl (2001) 0.81
Long-term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulates urinary nitrate and cGMP excretion in rats. Cardiovasc Res (1994) 0.81
Dose-related effect of intravenous L-arginine on muscular blood flow of the calf in patients with peripheral vascular disease: a H215O positron emission tomography study. Clin Sci (Lond) (1997) 0.81
Urinary nitrate excretion is increased in cardiac transplanted patients with acute graft rejection. Clin Transplant (1996) 0.80
The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis (1996) 0.80
Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man. Clin Sci (Lond) (1993) 0.80
Lovastatin maintains nitric oxide--but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery. Atherosclerosis (1999) 0.79
Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans. J Endocrinol Invest (1999) 0.79
Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Int J Clin Pharmacol Ther (1996) 0.78
Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy. Cardiovasc Res (2000) 0.78
Negative association of L-arginine methylation products with oocyte numbers. Hum Reprod (2010) 0.78
Increased urinary nitrate excretion in rats with adjuvant arthritis. Ann Rheum Dis (1994) 0.77
Dietary L-arginine normalizes endothelin-induced vascular contractions in cholesterol-fed rabbits. J Cardiovasc Pharmacol (1998) 0.77
[Endothelial dysfunction in peripheral arterial occlusive disease: from basic research to clinical use]. Vasa (1997) 0.76
[Comments on the contribution by Prof. Dr. S. H. Hohnloser. Sotalol]. Internist (Berl) (1995) 0.75
Is asymmetric dimethylarginine a novel marker of atherosclerosis? Circulation (2000) 0.75
[Intravenous immunoglobulins. Basic principles, selection criteria and indications for preventive and therapeutic administration]. Med Klin (Munich) (1995) 0.75
[Restenosis after percutaneous transluminal angioplasty: I. Etiology and clinical significance]. Vasa (1996) 0.75
[Restenosis after percutaneous transluminal angioplasty: II. Possibilities for pharmacologic intervention]. Vasa (1996) 0.75
[Volume replacement therapy with human albumin. Basic principles, differential indications, alternatives]. Med Klin (Munich) (1993) 0.75
Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid. Br J Clin Pharmacol (1996) 0.75
[Pathogenetic aspects of the L-arginine-NO metabolic pathway in arteriosclerosis and possible therapeutic aspects]. Vasa (1996) 0.75